|他仑帕奈|CsnPharm

CAS No.: 161832-65-1

Talampanel Catalog No. CSN13591

Synonyms: GYKI-53773;LY-300164;Gyki-53405

Talampanel, a potent and selective AMPA-receptor antagonist, is a potential antiepileptic drug (AED).

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Talampanel, a potent and selective AMPA-receptor antagonist, is a potential antiepileptic drug (AED).
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00034814	Epilepsy	Phase 2	Completed	-	-
NCT00004576	Dyskinesias P... more >>arkinson Disease Collapse <<	Phase 2	Completed	-	United States, Maryland ... more >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Collapse <<
NCT00057460	Healthy	Phase 2	Completed	-	United States, Maryland ... more >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Collapse <<

更多
参考文献

[1] Paizs M, Tortarolo M, et al. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler. 2011 Sep;12(5):340-4.
[2] Langan YM, Lucas R, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003 Jan;44(1):46-53.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.9641 mL
- 14.8204 mL
- 29.6408 mL
- 5 mM
- 0.5928 mL
- 2.9641 mL
- 5.9282 mL
- 10 mM
- 0.2964 mL
- 1.4820 mL
- 2.9641 mL

技术信息

CAS号	161832-65-1	储存条件	粉末 Keep in dark place,Sealed in dry,2-8°C 液体 -20°C:3-6 月 -80°C:12月
分子式	C19H19N3O3	运输	蓝冰
分子量	337.37	别名	GYKI-53773;LY-300164;Gyki-53405;LY-293606

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00034814	Epilepsy	Phase 2	Completed	-	-
NCT00004576	Dyskinesias P... more >>arkinson Disease Collapse <<	Phase 2	Completed	-	United States, Maryland ... more >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Collapse <<
NCT00057460	Healthy	Phase 2	Completed	-	United States, Maryland ... more >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Collapse <<
NCT00062504	Glioblastoma Multiforme ... more >> Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Mixed Oligoastrocytoma Collapse <<	Phase 2	Terminated	-	-
NCT00064363	Brain and Central Nervous Syst... more >>em Tumors Collapse <<	Phase 2	Completed	-	United States, Maryland ... more >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Collapse <<
NCT00108667	Parkinson Disease	Phase 2	Completed	-	United States, Maryland ... more >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Collapse <<
NCT00267592	Glioblastoma Multiforme	Phase 2	Completed	-	-
NCT00696332	ALS	Phase 2	Completed	-	-
NCT00964730	Healthy	Phase 1	Completed	-	United States, North Dakota ... more >> Cetero Research - Fargo Fargo, North Dakota, United States, 58104 Collapse <<
NCT00868361	Healthy	Phase 1	Terminated(Poor recruitment of... more >> fast and slow acetylators) Collapse <<	-	United States, Wisconsin ... more >> Covance Clinical Pharmacology Inc. Madison, Wisconsin, United States, 53704 Collapse <<
NCT00036296	Dyskinesias P... more >>arkinson Disease Movement Disorders Collapse <<	Phase 1 Phase 2	Completed	-	-
NCT00982150	Amyotrophic Lateral Sclerosis	Phase 2	Terminated(Core study unsucces... more >>sful) Collapse <<	-	-

Talampanel Catalog No. CSN13591

靶点选择性

请登录您的专属账户

确认信息